Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular outcomes
Pharma
Lilly dives deep into Foundayo's cardio perks in T2D, obesity
The data represent the deepest look so far at Foundayo’s cardiovascular potential in patients with type 2 diabetes and obesity.
Fraiser Kansteiner
Oct 1, 2026 11:38am
FDA approves Lilly's Mounjaro to reduce risk of cardio events
Aug 28, 2026 10:52am
Wegovy tops Zepbound on CV risk reduction in real-world study
Sep 2, 2025 11:33am
Novo's oral semaglutide shows heart benefits
Oct 21, 2024 10:09am
Novo bolsters star power of obesity blockbuster Wegovy
May 14, 2024 11:40am
ESC says SGLT2s like Farxiga are first-line treatment in HF
Aug 28, 2021 1:35pm
